Skip to main content
SpringerLink
Log in

Current understanding of the effect of sodium–glucose co-transporter-2 inhibitors in Asian patients with diabetes mellitus

  • Introduction to Mini-Reviews
  • Published:
Diabetology International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–288.

    Article  CAS  Google Scholar 

  2. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B, EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–34.

    Article  CAS  Google Scholar 

  3. Kaku K, Lee J, Mattheus M, Kaspers S, George J, Woerle HJ, EMPA-REG OUTCOME® Investigators. Empagliflozin and cardiovascular outcomes in Asian patients with type 2 diabetes and established cardiovascular disease—results from EMPA-REG OUTCOME(®). Circ J. 2017;81(2):227–34.

    Article  CAS  Google Scholar 

  4. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.

    Article  CAS  Google Scholar 

  5. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Metabolism and Endocrinology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan

    Hirotaka Watada

  2. Sportology Center, Juntendo University Graduate School of Medicine, Tokyo, Japan

    Hirotaka Watada

  3. Center for Therapeutic Innovations in Diabetes, Juntendo University Graduate School of Medicine, Tokyo, Japan

    Hirotaka Watada

  4. Center for Identification of Diabetic Therapeutic Targets, Juntendo University Graduate School of Medicine, Tokyo, Japan

    Hirotaka Watada

Authors
  1. Hirotaka Watada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hirotaka Watada.

Ethics declarations

Conflict of interest

HW received honoraria from Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Fujifilm, Kyowa Kirin, Merck Sharp and Dohme, Mitsubishi Tanabe Pharma, Novo Nordisk, Ono Pharmaceutical, Sanofi, Sanwa Kagaku Kenkyusho, Sumitomo Dainippon Pharma, Takeda Pharmaceutical and Terumo, also received subsidies or donations from Boehringer Ingelheim, Eli Lilly, Kowa, Novartis, Sanofi, Sanwa Kagaku Kenkyusho and Yakult Honsha, also received subsidies or donations from Abbott Japan, Astellas Pharma, Boehringer Ingelheim, Daiichi Sankyo, Kissei Pharmaceutical, Kyowa Kirin, Merck Sharp and Dohme, Mitsubishi Tanabe Pharma, Novartis Pharma, Novo Nordisk, Ono Pharmaceutical, Pfizer, Sanofi, Sumitomo Dainippon Pharma, Taisho Toyama Pharmaceutical and Teijin, and belongs to endowed departments by Boehringer Ingelheim, Kowa, Merck Sharp and Dohme, Mitsubishi Tanabe Pharma, Ono Pharmaceutical, Sanwa Kagaku Kenkyusho, Soiken and Takeda Pharmaceutical.

Ethical approval

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Watada, H. Current understanding of the effect of sodium–glucose co-transporter-2 inhibitors in Asian patients with diabetes mellitus. Diabetol Int 11, 242–244 (2020). https://doi.org/10.1007/s13340-020-00443-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13340-020-00443-9

Keywords

Search

Navigation